
Quarterly report 2025-Q3
added 11-12-2025
AcelRx Pharmaceuticals Net Debt 2011-2026 | ACRX
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt AcelRx Pharmaceuticals
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | -6.59 M | -5.4 M | 10.5 M | -76 M | -33.8 M | -58.8 M | -87 M | -35.1 M | -74 M | -32 M | 11.3 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 11.3 M | -87 M | -35.2 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Drug manufacturers industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Aerie Pharmaceuticals
AERI
|
-11.1 M | - | - | $ 754 M | ||
|
Alimera Sciences
ALIM
|
-11.2 M | - | - | $ 142 M | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
-22.5 M | - | 0.86 % | $ 117 M | ||
|
Agile Therapeutics
AGRX
|
-676 K | - | 10.11 % | $ 58.2 M | ||
|
Canopy Growth Corporation
CGC
|
193 M | $ 1.08 | -0.23 % | $ 116 M | ||
|
Cronos Group
CRON
|
-1.07 B | $ 2.64 | 0.57 % | $ 1.37 B | ||
|
Catalent
CTLT
|
4.58 B | - | - | $ 11.5 B | ||
|
Avadel Pharmaceuticals plc
AVDL
|
-49.7 M | - | - | $ 2.06 B | ||
|
Evolus
EOLS
|
94.8 M | $ 6.13 | 9.66 % | $ 395 M | ||
|
China Pharma Holdings
CPHI
|
-4.73 M | $ 0.58 | - | $ 10.1 M | ||
|
DURECT Corporation
DRRX
|
-10.4 M | - | - | $ 50.1 M | ||
|
Cumberland Pharmaceuticals
CPIX
|
-12.7 M | $ 3.74 | 1.91 % | $ 52.6 M | ||
|
Eagle Pharmaceuticals
EGRX
|
2.43 M | - | -39.89 % | $ 27.7 M | ||
|
Calliditas Therapeutics AB (publ)
CALT
|
-931 M | - | -0.1 % | $ 2.03 B | ||
|
Endo International plc
ENDP
|
7.37 B | - | - | $ 28.9 M | ||
|
HEXO Corp.
HEXO
|
-150 M | - | 2.45 % | $ 38.1 M | ||
|
Evoke Pharma
EVOK
|
-2.96 M | - | - | $ 36.6 M | ||
|
Harrow Health
HROW
|
178 M | $ 38.84 | -0.97 % | $ 1.43 B | ||
|
Aurora Cannabis
ACB
|
285 M | $ 3.62 | -0.72 % | $ 86.3 M | ||
|
Athenex
ATNX
|
-28.3 M | - | -23.39 % | $ 1.76 M | ||
|
Jupiter Wellness
JUPW
|
-21.7 K | - | - | $ 33.6 M | ||
|
Emergent BioSolutions
EBS
|
338 M | $ 8.55 | -2.51 % | $ 438 M | ||
|
Assertio Holdings
ASRT
|
-34 M | $ 11.99 | -0.66 % | $ 852 M | ||
|
Bausch Health Companies
BHC
|
21.1 B | $ 5.67 | 0.8 % | $ 2.07 B | ||
|
Lannett Company
LCI
|
529 M | - | 1.15 % | $ 7.11 M | ||
|
Neoleukin Therapeutics
NLTX
|
-146 M | - | - | $ 193 M | ||
|
OrganiGram Holdings
OGI
|
90.7 M | $ 1.48 | 6.47 % | $ 402 M | ||
|
Organogenesis Holdings
ORGO
|
-131 M | $ 2.92 | 1.74 % | $ 384 M | ||
|
Perrigo Company plc
PRGO
|
3.1 B | $ 11.59 | -0.86 % | $ 1.61 B | ||
|
Sundial Growers
SNDL
|
-28.4 M | $ 1.55 | 0.63 % | $ 3.37 M | ||
|
TherapeuticsMD
TXMD
|
3.68 M | $ 2.17 | 0.46 % | $ 22.7 M | ||
|
ProPhase Labs
PRPH
|
-6.41 M | - | - | $ 5.07 M | ||
|
Veru
VERU
|
-20.9 M | $ 2.51 | - | $ 339 M | ||
|
Viatris
VTRS
|
16.8 B | $ 14.56 | -1.05 % | $ 17.5 B | ||
|
Radius Health
RDUS
|
-111 M | - | - | $ 1.42 B | ||
|
Rockwell Medical
RMTI
|
691 K | $ 0.88 | -1.56 % | $ 20.5 M | ||
|
cbdMD
YCBD
|
-521 K | $ 0.76 | -1.04 % | $ 3.28 M | ||
|
Pacira BioSciences
PCRX
|
317 M | $ 23.08 | 0.96 % | $ 1.07 B | ||
|
PetIQ
PETQ
|
329 M | - | 1.64 % | $ 400 M | ||
|
OptiNose
OPTN
|
-72.2 M | - | - | $ 1.08 B | ||
|
PLx Pharma
PLXP
|
-21.8 M | - | -27.8 % | $ 2.56 M | ||
|
Recro Pharma
REPH
|
-6.65 M | - | -4.76 % | $ 65.3 M | ||
|
Relmada Therapeutics
RLMD
|
-2.5 M | $ 4.47 | -6.29 % | $ 135 M | ||
|
SCYNEXIS
SCYX
|
-19.1 M | $ 0.77 | -1.29 % | $ 38.4 M | ||
|
Solid Biosciences
SLDB
|
-70.9 M | $ 5.76 | -6.19 % | $ 235 M | ||
|
Sonoma Pharmaceuticals
SNOA
|
-5.29 M | $ 2.77 | -1.07 % | $ 3.44 M | ||
|
Tricida
TCDA
|
-7.08 M | - | - | $ 3.25 M | ||
|
Tilray
TLRY
|
14.4 M | $ 7.35 | 0.62 % | $ 4.54 B | ||
|
Zynerba Pharmaceuticals
ZYNE
|
-50.3 M | - | - | $ 55.5 M |